Services

Toxicology

Pharmacology

Animal Model Development

Medical Device Testing

In Vitro Screening

Custom Assay Development

Vivarium Rental

Histology

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Species

Non-human Primates

Dogs

Minipigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Careers

Request a Quote

Logo
☰
  • Services ⌄
    • Toxicology
    • Pharmacology
    • Animal Model Development
    • Medical Device Testing
    • In Vitro Screening
    • Custom Assay Development
    • Vivarium Rental
    • Histology
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Minipigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Careers
    • Request a Quote

FDA Issues Two Final Guidances: Use of EHRs, Electronic OTC Monograph Submissions

  • Post author:PacConAdmin
  • Post published:July 24, 2024
  • Post category:Uncategorized

The FDA has finalized its guidance on the use of electronic health records (EHR) or medical claims data in clinical studies to support a regulatory decision for effectiveness or safety.…

Continue ReadingFDA Issues Two Final Guidances: Use of EHRs, Electronic OTC Monograph Submissions

FDA Seeking Info to Develop Guidances on Host Cell Protein Risk and Biosimilars

  • Post author:PacConAdmin
  • Post published:July 24, 2024
  • Post category:Uncategorized

In its efforts to develop new guidances, the FDA is seeking information and comments on evaluating and mitigating the immunogenicity risk of host cell proteins (HCP) and the best way…

Continue ReadingFDA Seeking Info to Develop Guidances on Host Cell Protein Risk and Biosimilars

Merck Trial Shows Infants Protected From RSV by Antibody-Based Vaccine

  • Post author:PacConAdmin
  • Post published:July 24, 2024
  • Post category:Uncategorized

Merck announced that its investigational monoclonal antibody designed to protect infants from respiratory syncytial virus (RSV) disease met its primary safety and efficacy endpoints. Source: Drug Industry Daily

Continue ReadingMerck Trial Shows Infants Protected From RSV by Antibody-Based Vaccine

House Committee Report Says PBM Rebate Payments Stifle Generic Drugs

  • Post author:PacConAdmin
  • Post published:July 24, 2024
  • Post category:Uncategorized

Prescription benefit managers (PBM) use drug rebate payments to promote use of brand name drugs instead of generics, says a report released ahead of a House Committee on Oversight and…

Continue ReadingHouse Committee Report Says PBM Rebate Payments Stifle Generic Drugs

FDA Includes Interchangeables in New Guidance on CMC Changes for Biosimilars

  • Post author:PacConAdmin
  • Post published:July 23, 2024
  • Post category:Uncategorized

The FDA offers recommendations on what’s needed to support chemistry, manufacturing and controls (CMC) changes for biosimilars and interchangeable biosimilar products, in a new draft guidance. Source: Drug Industry Daily

Continue ReadingFDA Includes Interchangeables in New Guidance on CMC Changes for Biosimilars

Quick Notes: Drug Approvals — July 23, 2024

  • Post author:PacConAdmin
  • Post published:July 23, 2024
  • Post category:Uncategorized

This edition of Quick Notes focuses on FDA approval for Roche’s Vabysmo, reintroduction of Susvimo following a recall, EC approval of Dupixent and Samsung Bioepis’ Soliris biosimilar. Source: Drug Industry…

Continue ReadingQuick Notes: Drug Approvals — July 23, 2024

FDA Increases Foreign CGMP Inspections in 2023

  • Post author:PacConAdmin
  • Post published:July 23, 2024
  • Post category:Uncategorized

The FDA significantly increased foreign inspections in fiscal 2023 while domestic inspections remained flat, according to the agency’s latest annual inspection report. Source: Drug Industry Daily

Continue ReadingFDA Increases Foreign CGMP Inspections in 2023

Regeneron Fires Back at DOJ’s Charges of False Claim Act Violations

  • Post author:PacConAdmin
  • Post published:July 23, 2024
  • Post category:Uncategorized

The Department of Justice’s complaint against Regeneron that the company’s single cash-or-credit price is a violation of the False Claims Act “is not only incompatible with the text of the…

Continue ReadingRegeneron Fires Back at DOJ’s Charges of False Claim Act Violations

Legislative Update — Week of July 22, 2024

  • Post author:PacConAdmin
  • Post published:July 22, 2024
  • Post category:Uncategorized

As the second session of the 118th Congress begins, FDAnews will track important pending legislation, that has been acted on since Dec. 31, 2023 to keep you updated on laws…

Continue ReadingLegislative Update — Week of July 22, 2024

Final Guidance Focuses on Radiolabeled Mass Balance Studies of Investigational Drugs

  • Post author:PacConAdmin
  • Post published:July 22, 2024
  • Post category:Uncategorized

The FDA has issued a final guidance with recommendations on clinical pharmacology considerations for conducting human radiolabeled mass balance studies, including deciding whether and when to conduct the study, designing…

Continue ReadingFinal Guidance Focuses on Radiolabeled Mass Balance Studies of Investigational Drugs
  • Go to the previous page
  • 1
  • …
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • …
  • 143
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:
6042 Cornerstone Court W
Suite E
San Diego, CA 92121
Social::
© 2025 BioLegacy Research. All rights reserved.
BioLegacy research is a PharmaLegacy Laboratories company